Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PG-102

Other · developed by RANI Therapeutics

Phase 1 Most advanced trial
RANI Developer
1 Registered trials

What is PG-102?

PG-102 is a drug studied for the treatment of obesity.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Metabolic
Developer
RANI Therapeutics (RANI)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06891287 Phase 1 Obesity Recruiting RANI

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Obesity

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the RANI page.

Follow RANI, the company behind PG-102

See RANI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RANI catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.